ELOX

Eloxx Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company developing small-molecule drugs that coax the body's protein-building machinery to "read through" genetic errors called nonsense mutations, which cause rare diseases like Alport syndrome. Its lead investigational drug, exaluren, aims to restore full-length functional proteins in patients with these conditions. Founded in 2013 by two scientists, the company went public in 2017 through a reverse merger with Sevion Therapeutics, and its name echoes the "ELX" prefix of its drug compounds.